The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial
Abstract
IMPORTANCE: Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients with remitted first-episode psychosis (FEP) showed higher relapse rates but no other disadvantages compared with maintenance treatment; however, long-term effects on recovery have not been studied before. OBJECTIVE: To compare rates of recovery in patients with remitted FEP after 7 years of follow-up of a dose reduction/discontinuation (DR) vs maintenance treatment (MT) trial. DESIGN: Seven-year follow-up of a 2-year open randomized clinical trial comparing MT and DR. SETTING: One hundred twenty-eight patients participating in the original trial were recruited from 257 patients with FEP referred from October 2001 to December 2002 to 7 mental health care services in a 3.2 million-population catchment area. Of these, 111 patients refused to participate and 18 patients did not experience remission. PARTICIPANTS After 7 years, 103 patients (80.5%) of 128 patients who were included in the original trial were located and consented to follow-up assessment. INTERVENTION: After 6 months of remission, patients were randomly assigned to DR strategy or MT for 18 months. After the trial, treatment was at the discretion of the clinician. MAIN OUTCOMES AND MEASURES: Primary outcome was rate of recovery, defined as meeting the criteria of symptomatic and functional remission. Determinants of recovery were examined using logistic regression analysis; the treatment strategy (MT or DR) was controlled for baseline parameters. RESULTS: The DR patients experienced twice the recovery rate of the MT patients (40.4% vs 17.6%). Logistic regression showed an odds ratio of 3.49 (P = .01). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates. CONCLUSIONS AND RELEVANCE: Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT. To our knowledge, this is the first study showing long-term gains of an early-course DR strategy in patients with remitted FEP. Additional studies are necessary before these results are incorporated into general practice. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16228411.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“That is, relapses are not distributed evenly across time but tend to occur predominantly around the point of drug cessation.”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
In the citing paper
“It appears that relapse rates are raised in the discontinuation group for 1–3 years following a switch to placebo, before converging with relapse rates of medicated patients thereafter.3,56–59”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
In the citing paper
“one found 43% of the original cohort of patients relapsed in the first year, 21.5% in the second year, and just 3.7% a year in each of the 5 years following57,61”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,350
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.10.004 · Cited by 1,071
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434
Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
Self-citationGrace, A. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.011 · Cited by 225
Cited by
Sorted by citations
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Improving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Maj, M., van Os, J., De Hert, M., Gaebel, W., Galderisi, S., Green, M. F., Guloksuz, S., Harvey, P. D., Jones, P. B., Malaspina, D., et al. (2021) · World Psychiatry · doi:10.1002/wps.20809 · Cited by 285
Santesteban-Echarri, O., Paino, M., Rice, S., González-Blanch, C., McGorry, P., Gleeson, J., & Alvarez-Jimenez, M. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.09.007 · Cited by 268
Davidson, L. (2016) · Health Affairs · doi:10.1377/hlthaff.2016.0153 · Cited by 290
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257
Emerging perspectives from the hearing voices movement: implications for research and practice
Corstens, D., Longden, E., McCarthy-Jones, S., Waddingham, R., & Thomas, N. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu007 · Cited by 256
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244
Predictors of outcome in early-onset psychosis: a systematic review
Díaz‐Caneja, C. M., Pina‐Camacho, L., Rodríguez-Quiroga, A., Fraguas, D., Parellada, M., & Arango, C. (2015) · Schizophrenia · doi:10.1038/npjschz.2014.5 · Cited by 235
More treatment but no less depression: The treatment-prevalence paradox
Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P., & Monroe, S. M. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102111 · Cited by 213
Tiihonen, J., Tanskanen, A., & Taipale, H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17091001 · Cited by 196
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
GOFF, D. C., Falkai, P., Fleischhacker, W. W., Girgis, R. R., Kahn, R. S., Uchida, H., Zhao, J., & Lieberman, J. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091016 · Cited by 201
Leonhardt, B. L., Huling, K., Hamm, J. A., Roe, D., Hasson-Ohayon, I., McLeod, H. J., & Lysaker, P. H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1378099 · Cited by 195
Bergström, T., Seikkula, J., Alakare, B., Mäki, P. H., Köngäs‐Saviaro, P., Taskila, J. J., Tolvanen, A. J., & Aaltonen, J. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.039 · Cited by 175
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Lähteenvuo, M., & Tiihonen, J. (2021) · Drugs · doi:10.1007/s40265-021-01556-4 · Cited by 178
Jansen, J. E., Gleeson, J., Bendall, S., Rice, S., & Alvarez-Jimenez, M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.016 · Cited by 144
Hui, C. L. M., Honer, W. G., Lee, E. H. M., Chang, W. C., Chan, S. K. W., Chen, E. S. M., Pang, E. P. F., Lui, S. S. Y., Chung, D. W. S., Yeung, W. S., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30090-7 · Cited by 149
Kidd, S. A., Davidson, L., Frederick, T. J., & Kral, M. J. (2017) · American Journal of Community Psychology · doi:10.1002/ajcp.12214 · Cited by 136
Keating, D., McWilliams, S., Schneider, I., Hynes, C., Cousins, G., Strawbridge, J., & Clarke, M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013881 · Cited by 135
Novick, D., Montgomery, W., Treuer, T., Aguado, J., Kraemer, S., & Haro, J. M. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0560-4 · Cited by 127
Harrow, M., Jobe, T. H., & Faull, R. N. (2014) · Psychological Medicine · doi:10.1017/s0033291714000610 · Cited by 116
Rubio, J., Schoretsanitis, G., John, M., Tiihonen, J., Taipale, H., Guinart, D., Malhotra, A., Correll, C., & Kane, J. (2020) · Lancet psychiatry · doi:10.1016/s2215-0366(20)30264-9 · Cited by 96
Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia
Stroup, T. S., Olfson, M., Huang, C., Wall, M. M., Goldberg, T., Devanand, D. P., & Gerhard, T. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0042 · Cited by 112
Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery?
Harrow, M., & Jobe, T. H. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt034 · Cited by 106
Wils, R. S., Gotfredsen, D. R., Hjorthøj, C. R., Austin, S. F., Albert, N., Secher, R. G., Thorup, A. A. E., Mors, O. N., & Nordentoft, M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.10.030 · Cited by 106
Understanding Psychosis and Schizophrenia
Cooke, A. (2014) · Cited by 163
Interventions for prodromal stage of psychosis
Kuharić, D. B., Kekin, I., Hew, J., Kuzman, M. R., & Puljak, L. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012236.pub2 · Cited by 116
Japanese Society of Neuropsychopharmacology (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12193 · Cited by 105
Husa, A. P., Moilanen, J. S., Murray, G. K., Marttila, R., Haapea, M., Rannikko, I., Barnett, J. H., Jones, P. B., Isohanni, M. K., Remes, A. M., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.10.085 · Cited by 101
Antipsychotic treatment of schizophrenia: An update
Bruijnzeel, D. M., Suryadevara, U., & Tandon, R. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.08.002 · Cited by 105
Hodgekins, J., Birchwood, M. J., Christopher, R., Marshall, M., Coker, S., Everard, L., Lester, H. E., Jones, P. B., Amos, T., Singh, S. P., et al. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.153486 · Cited by 99
Kotov, R., Fochtmann, L. J., Li, K., Tanenberg‐Karant, M., Constantino, E. A., Rubinstein, J. E., Perlman, G., Velthorst, E., Fett, A.-K. J., Carlson, G. A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16101191 · Cited by 99
Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
Yin, J., Barr, A. M., Ramos‐Miguel, A., & Procyshyn, R. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160606093602 · Cited by 99
Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
Rubio, J. M., Taipale, H. T., Tanskanen, A. J., Correll, C. U., Kane, J. M., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab063 · Cited by 92
Moncrieff, J., Crellin, N. E., Stansfeld, J. L., Cooper, R. E., Marston, L., Freemantle, N., Lewis, G., Hunter, R. M., Johnson, S., Barnes, T. R. E., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00258-4 · Cited by 95
Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review
Bozzatello, P., Bellino, S., & Rocca, P. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00067 · Cited by 89
Is It Possible to Predict the Future in First-Episode Psychosis?
Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T. J. S., Rikandi, E., Lindgren, M., Kieseppä, T., & Raij, T. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00580 · Cited by 96
Alvarez-Jimenez, M., O’Donoghue, B., Thompson, A., Gleeson, J. F., Bendall, S., Gonzalez-Blanch, C., Killackey, E., Wunderink, L., & McGorry, P. D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0331-x · Cited by 80
Antipsychotic maintenance treatment: time to rethink
Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 81
Huhtaniska, S., Jääskeläinen, E., Hirvonen, N., Remes, J. J., Murray, G. K., Veijola, J. M., Isohanni, M. K., & Miettunen, J. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2574 · Cited by 79
Functional recovery in patients with schizophrenia: recommendations from a panel of experts
Lahera, G., Gálvez, J. L., Sánchez, P., Martínez-Roig, M., Pérez-Fuster, J. V., García‐Portilla, M. P., Herrera, B., & Roca, M. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1755-2 · Cited by 80
Kishi, T., Ikuta, T., Matsui, Y., Inada, K., Matsuda, Y., Mishima, K., & Iwata, N. (2018) · Psychological Medicine · doi:10.1017/s0033291718001393 · Cited by 77
Begemann, M., Thompson, I. A., Veling, W., Gangadin, S. S., Geraets, C. N. W., Hag, E. V., Müller-Kuperus, S. J., Oomen, P. P., Voppel, A., van der Gaag, M., et al. (2020) · Trials · doi:10.1186/s13063-019-3822-5 · Cited by 75
Morant, N. J., Azam, K., Johnson, S., & Moncrieff, J. (2017) · Journal of Mental Health · doi:10.1080/09638237.2017.1370637 · Cited by 76
Antipsychotic Medication During the Critical Period Following Remission From First-Episode Psychosis
McGorry, P. D., Álvarez‐Jiménez, M., & Killackey, E. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.264 · Cited by 73
Palaniyappan, L. K. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.028 · Cited by 77
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.013 · Cited by 67
Taipale, H., Tanskanen, A., Correll, C., & Tiihonen, J. (2022) · Lancet psychiatry · doi:10.1016/s2215-0366(22)00015-3 · Cited by 43
Harrow, M., Jobe, T. H., Faull, R. N., & Yang, J. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.06.069 · Cited by 69
Højlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00078-x · Cited by 67
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Davidson, M., Saoud, J. B., Staner, C., Noël, N., Werner, S., Luthringer, E., Walling, D. P., Weiser, M., Harvey, P. D., Strauss, G. P., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac013 · Cited by 66
Antipsychotic treatment – a systematic literature review and meta-analysis of qualitative studies
Bjørnestad, J. R., Lavik, K. O., Davidson, L., Hjeltnes, A., Moltu, C., & Veseth, M. (2019) · Journal of Mental Health · doi:10.1080/09638237.2019.1581352 · Cited by 73
Stegmayer, K., Walther, S., & van Harten, P. N. (2018) · CNS Drugs · doi:10.1007/s40263-018-0494-8 · Cited by 65
Bowtell, M., Ratheesh, A., McGorry, P., Killackey, E., & O'Donoghue, B. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.010 · Cited by 62
Peralta, V., de Jalón, E. G., Moreno-Izco, L., Peralta, D., Janda, L., Sánchez-Torres, A. M., Cuesta, M. J., SEGPEPs Group, Ballesteros, A., Gil‐Berrozpe, G. J., et al. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab145 · Cited by 63
Unmet needs in the management of schizophrenia
Torres‐González, F., Ibáñez-Casas, I., Saldivia, S., Ballester, D., Pamela Grandón, F., Moreno‐Küstner, B., Xavier, M., & Gómez-Beneyto, M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41063 · Cited by 71
Recent advances in understanding schizophrenia
Haller, C. S., Padmanabhan, J. L., Lizano, P. L., Torous, J. B., & Keshavan, M. S. (2014) · F1000Prime Reports · doi:10.12703/p6-57 · Cited by 65
Bogers, J. P. A. M., Hambarian, G., Schmidt, N. W., Vermeulen, J. M., & de Haan, L. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac138 · Cited by 61
Accepting and Working with Voices: The Maastricht Approach
Corstens, D., Escher, S., & Romme, M. (2008) · Wiley eBooks · doi:10.1002/9780470699652.ch23 · Cited by 56
Rates and Predictors of Relapse in First-Episode Psychosis: An Australian Cohort Study
Brown, E., Bedi, G., McGorry, P. D., & O'Donoghue, B. N. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa017 · Cited by 57
Cooper, R. E., Laxhman, N., Crellin, N. E., Moncrieff, J., & Priebe, S. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.020 · Cited by 62
The Pharmacologic Treatment of Schizophrenia—2021
GOFF, D. C. (2020) · JAMA · doi:10.1001/jama.2020.19048 · Cited by 56
Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
Fountoulakis, K. Ν., Dragioti, E., Antonis, T., Wikilund, T., Atmatzidis, X., Nimatoudis, I., Thys, E., Wampers, M., Hranov, L. G., Hristova, T., et al. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz053 · Cited by 54
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 53
Zhou, Y., Li, G., Li, D., Cui, H., & Ning, Y. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118756062 · Cited by 52
Taylor, M., & Jauhar, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319870033 · Cited by 51
Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 58
Moncrieff, J., Lewis, G., Freemantle, N., Johnson, S., Barnes, T. R. E., Morant, N. J., Pinfold, V., Hunter, R. M., Kent, L., Smith, R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030912 · Cited by 53
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
Cooper, R. E., Hanratty, É., Morant, N., & Moncrieff, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218711 · Cited by 49
How do people experience early intervention services for psychosis? A meta-synthesis.
Hansen, H., Stige, S. H., Davidson, L., Moltu, C., & Veseth, M. (2018) · Qualitative Health Research · doi:10.1177/1049732317735080 · Cited by 49
Moncrieff, J., Crellin, N. E., Long, M., Cooper, R. E., & Stockmann, T. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.08.035 · Cited by 49
Blackman, G., Oloyede, E., Horowitz, M. A., Harland, R., Taylor, D. M., MacCabe, J. H., & McGuire, P. K. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 49
Oedegaard, C. H., Davidson, L., Stige, B., Veseth, M., Blindheim, A. A., Garvik, L., Sørensen, J.-M. T., Søraa, Ø., & Engebretsen, I. M. S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02770-2 · Cited by 51
Damsgaard, J. B., & Angel, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052708 · Cited by 62
McOmish, C. E., Burrows, E. L., & Hannan, A. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12783 · Cited by 48
Schoretsanitis, G., Kane, J., Correll, C., & Rubio, J. (2021) · Schizophrenia bulletin · doi:10.1093/schbul/sbab091 · Cited by 41
Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis
Geyt, G. L., Awenat, Y. F., Tai, S., & Haddock, G. (2016) · Qualitative Health Research · doi:10.1177/1049732316634047 · Cited by 47
Castelein, S., Timmerman, M. E., PHAMOUS investigators, van der Gaag, M., & Visser, E. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.48 · Cited by 51
Dudek, E. M., & Dodell‐Feder, D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.020 · Cited by 45
Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., Hetrick, S., Realpe, A., Vail, L., Dawson, S., & Sullivan, S. A. (2018) · BJPsych Open · doi:10.1192/bjo.2018.17 · Cited by 44
Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health
Cotton, S., Filia, K., Ratheesh, A., Pennell, K., Goldstone, S. D., & McGorry, P. D. (2015) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-015-1140-0 · Cited by 47
Winton‐Brown, T., Elanjithara, T., Power, P., Coentre, R. M., Blanco-Polaina, P., & McGuire, P. K. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.09.029 · Cited by 44
Moriana, J. A., Gálvez-Lara, M., & Corpas, J. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.03.008 · Cited by 65
Takeuchi, H., Kantor, N., Sanches, M., Fervaha, G., Agid, O., & Remington, G. J. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.116.186007 · Cited by 44
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03822-5 · Cited by 44
Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43
Gaffey, K. J., Evans, D. S., & Walsh, F. P. (2016) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12325 · Cited by 42
Hasan, A. A., & Musleh, M. (2017) · Issues in Mental Health Nursing · doi:10.1080/01612840.2017.1317307 · Cited by 47
Drake, R. J., Nordentoft, M., Haddock, G., Arango, C., Fleischhacker, W. W., Glenthøj, B., Leboyer, M., Leucht, S., Leweke, M., McGuire, P., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv015 · Cited by 42
Using Open Questions to Understand 650 People’s Experiences With Antipsychotic Drugs
Read, J., & Sacia, A. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa002 · Cited by 41
Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
Rubio, J. M., Taipale, H., Correll, C. U., Tanskanen, A., Kane, J. M., & Tiihonen, J. (2020) · Psychological Medicine · doi:10.1017/s0033291719001296 · Cited by 45
Štuhec, M., Hahn, M., Tašková, I., Bayraktar, İ., Fitzgerald, I., Molitschnig, L.-T., Tatarević, A., Lindner, N., Agnoletto, L., & da Costa, F. A. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01643-4 · Cited by 40
Very long-term outcome of schizophrenia
Volavka, J., & Vevera, J. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13094 · Cited by 40
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain.
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz-Marsá, M., García-Portilla, M., Gutiérrez-Rojas, L., Olivares, J. M., Rico-Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.03.006 · Cited by 25
A qualitative study of medication adherence amongst people with schizophrenia
Clifford, L., Crabb, S., Turnbull, D. A., Hahn, L. A., & Galletly, C. A. (2020) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2020.06.002 · Cited by 39
Metadata
- Authors
- Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J.
- Affiliations
- University Medical Center Groningen (NL)
- Corresponding author
- Wunderink, Lex
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2013-09-01
- Volume
- 70
- Issue
- 9
- Pages
- 913
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2125616168
- Cited by
- 567
- References
- 24
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 31 · 2023: 39 · 2022: 37 · 2021: 47 · 2020: 42 · 2019: 71 · 2018: 59 · 2017: 43 · 2016: 65 · 2015: 42 · 2014: 36 · 2013: 8
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Keywords
- first-episode psychosis, remission, antipsychotic dose reduction, antipsychotic discontinuation, long-term antipsychotic treatment, long-term recovery, functional remission, symptom remission, relapse
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Psychotic Disorders, Recurrence, Remission Induction, Antipsychotic Agents, Treatment Outcome, Age of Onset, Young Adult, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review